Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
Jun 1, 2019, 00:00
10.1016/j.jval.2019.02.005
https://www.valueinhealthjournal.com/article/S1098-3015(19)30119-6/fulltext
Title :
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30119-6&doi=10.1016/j.jval.2019.02.005
First page :
750
Section Title :
CORRECTIONS
Open access? :
Yes
Section Order :
750
Value in Health. 2019; 22(2):168-176.
DOI of original article: 10.1016/j.jval.2018.08.011
In the original published version of this article, Figure 1 on page 169 appeared incorrectly. The figure is shown correctly below:
EDDS indicates Kurtzke Expanded Disability Status Scale.
Categories :
Tags :
Regions :
ViH Article Tags :